Study on Blood Test for Predicting Treatment in Stage IIA Colon Cancer After Surgery

Inclusion Criteria

• Must have signed a consent form approved by the review board.
• Must have a performance status of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
• Must have a confirmed diagnosis of stage IIA colon cancer with specific tumor characteristics.
• Must be suitable for active monitoring without chemotherapy, as decided by the oncologist.
• The tumor must be located at least 12 cm from the anal verge, excluding certain rectal cancers.
• Must have had a complete tumor removal surgery within 14 to 60 days before joining the study.
• Must provide a tumor sample for testing.
• Must have adequate blood cell counts and organ function as determined by specific tests.
• Women of childbearing potential must have a negative pregnancy test before joining the study.
• Patients on certain blood thinners must agree to regular monitoring if they receive specific chemotherapy.

Exclusion Criteria

• Have a type of colon cancer other than adenocarcinoma.
• Have evidence of cancer spread beyond the colon.
• Have had a bowel perforation related to the tumor.
• Have a history of invasive colon cancer.
• Have had an organ transplant.
• Have received prior chemotherapy, targeted therapy, immunotherapy, or radiation for colorectal cancer.
• Have had another invasive cancer within the past 5 years, with some exceptions.
• Have multiple primary colon or rectal cancers.
• Have uncontrolled heart disease that would prevent using study drugs.
• Have severe nerve damage or active seizure disorder.
• Have an active infection requiring treatment.
• Have a known deficiency in a specific enzyme (DPD).
• Be pregnant or breastfeeding.
• Have other health issues that would make participating in the study unsafe.
• Have previously used a ctDNA test for managing colon cancer.